Skip to main content
Top
Published in: Clinical and Translational Oncology 1/2021

01-01-2021 | Breast Cancer | Research Article

Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer

Authors: A. S. Algebaly, R. S. Suliman, W. S. Al-Qahtani

Published in: Clinical and Translational Oncology | Issue 1/2021

Login to get access

Abstract

Background

About 5–10% of incidences of breast cancers have been reported as a result of germline mutations of BRCA genes. However, the mutational spectrum of BRCA1 and BRCA2 genes among breast cancer Saudi women patients is inadequate at present. Therefore, the present study aimed to report the specific germinal mutation of BRCA1 and BRCA2 in the entire coding regions, to investigate the prevalence rate of BRCA1 & BRCA2 mutations among Saudi women and the effect of these mutations, both benign and malignant tumors.

Methodology

A total of 270 tissue samples of benign and malignant breast tumors were collected from Saudi women patients, Riyadh, Saudi Arabia. Examination of BRCA1 and BRCA2 germline mutations was performed using heteroduplex DNA analysis (HDA) or single-stranded conformation analysis (SSCA). 177 breast cancer women with malignant tumors and 93 with benign tumors were enrolled in the study. A total of 62 out of 177 breast cancer patients carried a BRCA1 or BRCA2 mutation (54 BRCA1 and 8 BRCA2). The analysis was done using the Sanger sequence assay.

Results

Point and frameshift mutations through the entire coding area of the two genes indicated that all the mutations were germline alterations and of early-onset breast cancers. The mean ages of diagnosed breast cancer women for BRCA1 and BRCA2 mutation carriers were 36.3 (± 3.5) and 37.9 (± 3.7) years, whereas that of benign control was 35(± 2.5) years.

Conclusion

Point and frameshift mutations across the entire coding region of BRCA1 and BRCA2 are responsible for many breast cancers cases.
Literature
1.
go back to reference Ferlay J, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. 2018. Ferlay J, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. 2018.
2.
go back to reference Miki Y, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.CrossRef Miki Y, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.CrossRef
3.
go back to reference Abulkhair O, et al. Prevalence of BRCA1 and BRCA2 mutations among high-risk Saudi patients with breast cancer. J Global Oncol. 2018;3:1–9. Abulkhair O, et al. Prevalence of BRCA1 and BRCA2 mutations among high-risk Saudi patients with breast cancer. J Global Oncol. 2018;3:1–9.
4.
go back to reference ALmutlaq BA, et al. Options in breast reconstruction and plastic surgery in regard to surgeon perceptions and patients acceptance in Saudi Arabia. J Mod Plast Surg. 2017;7:50–64.CrossRef ALmutlaq BA, et al. Options in breast reconstruction and plastic surgery in regard to surgeon perceptions and patients acceptance in Saudi Arabia. J Mod Plast Surg. 2017;7:50–64.CrossRef
5.
go back to reference ALmutlaq BA, et al. The influence of women's positioning in breast measurements for subsequent breast plastic surgery. Am J Clin Med Res. 2018;6:10–14. ALmutlaq BA, et al. The influence of women's positioning in breast measurements for subsequent breast plastic surgery. Am J Clin Med Res. 2018;6:10–14.
6.
go back to reference Almutlaq BA, et al. Breast cancer in Saudi Arabia and its possible risk factors. J Cancer Policy. 2017;12:83–9.CrossRef Almutlaq BA, et al. Breast cancer in Saudi Arabia and its possible risk factors. J Cancer Policy. 2017;12:83–9.CrossRef
7.
go back to reference Alrashidi AG, et al. Knowledge and perceptions of common breast cancer risk factors in Northern Saudi Arabia. Asian Pac J Cancer Prev. 2017;18:2755–62.PubMedPubMedCentral Alrashidi AG, et al. Knowledge and perceptions of common breast cancer risk factors in Northern Saudi Arabia. Asian Pac J Cancer Prev. 2017;18:2755–62.PubMedPubMedCentral
8.
go back to reference Othman A, et al. Knowledge, attitudes and practices of breast cancer screening among women in Jordan. Health Care Women Int. 2015;36:578–92.CrossRef Othman A, et al. Knowledge, attitudes and practices of breast cancer screening among women in Jordan. Health Care Women Int. 2015;36:578–92.CrossRef
9.
go back to reference Fang M, et al. Characterization of mutations in BRCA1/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of chinese population. Oncol Lett. 2018;15:3068–74. Fang M, et al. Characterization of mutations in BRCA1/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of chinese population. Oncol Lett. 2018;15:3068–74.
10.
go back to reference Larsen MJ, et al. Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer: Basic Clin Res. 2014;8:145–55. Larsen MJ, et al. Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer: Basic Clin Res. 2014;8:145–55.
11.
go back to reference Blackwood MA, Barbara LW. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol. 1998;16:1969–77CrossRef Blackwood MA, Barbara LW. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol. 1998;16:1969–77CrossRef
12.
go back to reference Torres D, et al. Prevalence and penetration of BRCA1 and BRCA2 germline mutationss in Colombian breast cancer patients. Sci Rep. 2018:7:1–9. Torres D, et al. Prevalence and penetration of BRCA1 and BRCA2 germline mutationss in Colombian breast cancer patients. Sci Rep. 2018:7:1–9.
13.
go back to reference Ottini L, et al. BRCA1 and BRCA2 mutations status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003;63:342–7.PubMed Ottini L, et al. BRCA1 and BRCA2 mutations status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003;63:342–7.PubMed
14.
go back to reference Ediriweera DS, et al. Mapping the risk of snakebite in Sri Lanka-a national survey with geospatial analysis. PLoS Negl Trop Dis. 2016;10:1–14.CrossRef Ediriweera DS, et al. Mapping the risk of snakebite in Sri Lanka-a national survey with geospatial analysis. PLoS Negl Trop Dis. 2016;10:1–14.CrossRef
15.
go back to reference Kumar D, et al. Quantification of DNA extracted from formalin fixed paraffin-embedded tissue comparison of three techniques: effect on PCR efficiency. J Clin Diagn Res. 2016;10:BC01–3.PubMedPubMedCentral Kumar D, et al. Quantification of DNA extracted from formalin fixed paraffin-embedded tissue comparison of three techniques: effect on PCR efficiency. J Clin Diagn Res. 2016;10:BC01–3.PubMedPubMedCentral
16.
go back to reference Alcaide M, et al. A novel multiplex droplet digital pcr assay to identify and quantify KRAS mutations in clinical specimens. J Mol Diagn. 2019;21:214–27.CrossRef Alcaide M, et al. A novel multiplex droplet digital pcr assay to identify and quantify KRAS mutations in clinical specimens. J Mol Diagn. 2019;21:214–27.CrossRef
17.
go back to reference Nataraj AJ, et al. Single‐strand conformation polymorphism and heteroduplex analysis for gel‐based mutation detection. Electrophoresis. 1999;20:1177–85.CrossRef Nataraj AJ, et al. Single‐strand conformation polymorphism and heteroduplex analysis for gel‐based mutation detection. Electrophoresis. 1999;20:1177–85.CrossRef
18.
go back to reference Suvarna KS, Christopher L, John DB, editors. Bancroft's theory and practice of histological techniques E-Book. Elsevier Health Sciences; 2018. p. 213–20. Suvarna KS, Christopher L, John DB, editors. Bancroft's theory and practice of histological techniques E-Book. Elsevier Health Sciences; 2018. p. 213–20.
19.
go back to reference Tian H, Lawrence CB, James PL. Rapid detection of deletion, insertion, and substitution mutations via heteroduplex analysis using capillary-and microchip-based electrophoresis. Genome Res. 2000;10:1403–13.CrossRef Tian H, Lawrence CB, James PL. Rapid detection of deletion, insertion, and substitution mutations via heteroduplex analysis using capillary-and microchip-based electrophoresis. Genome Res. 2000;10:1403–13.CrossRef
20.
go back to reference Lancaster JM, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet. 1996;13:238–40.CrossRef Lancaster JM, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet. 1996;13:238–40.CrossRef
21.
go back to reference Apessos A, et al. Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center. Cancer Genet. 2018;220:1–12.CrossRef Apessos A, et al. Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center. Cancer Genet. 2018;220:1–12.CrossRef
22.
go back to reference Liu Y, et al. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. Mol Genet Genomic Med. 2019;7:e493.CrossRef Liu Y, et al. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. Mol Genet Genomic Med. 2019;7:e493.CrossRef
23.
go back to reference Bayraktar S, et al. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012;118:1515–22.CrossRef Bayraktar S, et al. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012;118:1515–22.CrossRef
24.
go back to reference Abusanad A. BRCA testing dichotomy in Saudi Arabia. J Global Oncol. 2019;5:1–2.CrossRef Abusanad A. BRCA testing dichotomy in Saudi Arabia. J Global Oncol. 2019;5:1–2.CrossRef
25.
go back to reference Comen E. et al. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women. Breast Cancer Res Treat. 2011;129:185–90.CrossRef Comen E. et al. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women. Breast Cancer Res Treat. 2011;129:185–90.CrossRef
26.
go back to reference Na B, et al. Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation. NPJ Breast Cancer. 2019;5:1–10.CrossRef Na B, et al. Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation. NPJ Breast Cancer. 2019;5:1–10.CrossRef
27.
go back to reference Lara K, et al. BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Biol Res. 2012;45:117–30.CrossRef Lara K, et al. BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Biol Res. 2012;45:117–30.CrossRef
28.
go back to reference Suliman et al. Role of human PTEN and TP53 sequence mutations in the etiology of breast cancer in Saudi Patients. Pak J Biol Sci. 2020;9:321–30.CrossRef Suliman et al. Role of human PTEN and TP53 sequence mutations in the etiology of breast cancer in Saudi Patients. Pak J Biol Sci. 2020;9:321–30.CrossRef
Metadata
Title
Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer
Authors
A. S. Algebaly
R. S. Suliman
W. S. Al-Qahtani
Publication date
01-01-2021
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 1/2021
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02385-9

Other articles of this Issue 1/2021

Clinical and Translational Oncology 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine